Alembic Pharma receives USFDA’s tentative approval for Alogliptin Tablet

16 Oct 2018 Evaluate

Alembic Pharmaceuticals has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Alogliptin Tablets, 6.25 mg, 12.5 mg and 25mg. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), NESINA Tablets, 6.25 mg, 12.5 mg and 25mg of Takeda Pharms USA.

Alogliptin Tablets, 6.25 mg, 12.5 mg and 25mg are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Alogliptin Tablets, 6.25 mg, 12.5 mg and 25mg has an estimated market size of $65.6 million for twelve months ending December 2017 according to IQVIA. Alembic now has a total of 78 ANDA approvals (64 final approvals and 14 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharma Share Price

839.00 -13.30 (-1.56%)
29-Dec-2025 13:06 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1723.00
Dr. Reddys Lab 1267.30
Cipla 1499.40
Zydus Lifesciences 904.05
Lupin 2095.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×